Published in PLoS One on November 10, 2010
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A (2014) 1.59
Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism. PLoS Genet (2014) 0.80
The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases. Am J Alzheimers Dis (Columbia) (2013) 0.76
Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat. PLoS One (2013) 0.76
Dopamine-Responsive Growth-Hormone Deficiency and Central Hypothyroidism in Sepiapterin Reductase Deficiency. JIMD Rep (2015) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27
D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci (2002) 2.25
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
A measure of striatal function predicts motor stereotypy. Nat Neurosci (2000) 1.81
Bilateral chorea-ballism associated with hyperthyroidism. Mov Disord (2004) 1.61
Levodopa motor complications in Parkinson's disease. Trends Neurosci (2000) 1.58
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci (2001) 1.57
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem (2009) 1.53
Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci (2000) 1.39
The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev (1999) 1.26
Chorea associated with thyroxine replacement therapy. Mov Disord (2005) 1.23
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med (2010) 1.23
Thyrotropin-releasing hormone precursor: characterization in rat brain. Science (1986) 1.20
Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci U S A (2008) 1.09
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis (2004) 1.07
Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci U S A (2009) 1.07
Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord (2008) 1.06
Immunohistochemical localization of thyrotropin-releasing hormone in the rat hypothalamus and pituitary. Endocrinology (1982) 1.05
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids (2002) 1.05
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis (2010) 1.04
Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience (1999) 1.02
Striosomes and mood dysfunction in Huntington's disease. Brain (2006) 1.02
Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol (2005) 0.98
Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain (2008) 0.96
Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord (2008) 0.95
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol (2000) 0.95
Processing of prothyrotropin-releasing hormone by the family of prohormone convertases. J Biol Chem (1997) 0.95
Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol (2000) 0.94
Parkinsonism and hyperthyroidism. Eur Neurol (1974) 0.93
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord (2007) 0.93
Identification of the thyrotropin-releasing hormone precursor, its processing products, and its coexpression with convertase 1 in primary cultures of hypothalamic neurons: anatomic distribution of PC1 and PC2. Endocrinology (1996) 0.92
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res (2006) 0.92
Pro-thyrotropin-releasing hormone processing by recombinant PC1. J Neurochem (1995) 0.91
Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia. Mov Disord (1998) 0.89
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis (2001) 0.88
Proliferation dynamics of germinative zone cells in the intact and excitotoxically lesioned postnatal rat brain. BMC Neurosci (2005) 0.88
Processing of prothyrotropin-releasing hormone (Pro-TRH) by bovine intermediate lobe secretory vesicle membrane PC1 and PC2 enzymes. Endocrinology (1995) 0.86
Three in one: case report supporting different origins of essential and parkinsonian tremors. Eur Neurol (2006) 0.86
Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson. Parkinsonism Relat Disord (2005) 0.85
Grafts of adult subependymal zone neuronal progenitor cells rescue hemiparkinsonian behavioral decline. Brain Res (2005) 0.84
Parkinson's disease after antithyroid treatment. Lancet (1988) 0.84
Immunolocalization of the thyrotropin-releasing hormone prohormone in the rat central nervous system. Endocrinology (1986) 0.84
Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type. Mov Disord (2007) 0.83
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Br Med J (Clin Res Ed) (1986) 0.83
Identification of the thyrotropin-releasing hormone-prohormone and its posttranslational processing in a transfected AtT20 tumoral cell line. Endocrinology (1993) 0.82
Intracellular sites of prothyrotropin-releasing hormone processing. J Biol Chem (1996) 0.81
Presence of Ras guanyl nucleotide-releasing protein in striosomes of the mature and developing rat. Neuroscience (2002) 0.81
Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res (2002) 0.81
Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment. Brain Res (1999) 0.81
Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Mol Neurobiol (1999) 0.80
The role of dopamine in regulation of thyrotropin-releasing hormone in the striatum and nucleus accumbens of the rat. Neuropeptides (1991) 0.80
Immunohistochemical localization in the rat brain of the precursor for thyrotropin-releasing hormone. Science (1985) 0.79
Post-translational processing of thyrotropin-releasing hormone precursor in rat brain: identification of 3 novel peptides derived from proTRH. Brain Res (1988) 0.79
Adenosine receptor agonists inhibit TRH-induced behaviour in rabbits: evidence for a main role of striatal A2 receptors. Behav Brain Res (1993) 0.77
The role of dopamine receptors in the release of thyrotropin-releasing hormone from the rat striatum and nucleus accumbens: an in vitro study. Neuropeptides (1993) 0.77
Systemic administration of thyrotropin-releasing hormone enhances striatal dopamine release in vivo. Brain Res (1990) 0.77
Autoimmune thyroid disease and segmental myoclonus. Mov Disord (2007) 0.76
Effects of SCH 23390 on thyrotropin-releasing hormone-induced behaviour in rabbits. Eur J Pharmacol (1989) 0.76
YM-14673, a thyrotropin-releasing hormone analogue, injected into the nucleus accumbens and the striatum produces repetitive jaw movements in rats. Eur J Pharmacol (1995) 0.76
Effects of repeated cocaine administration on the thyrotropin-releasing hormone level and receptors in the rat brain. Neuropeptides (1997) 0.76
Interactions between dopamine D1 and D2 receptors in the model of thyrotropin-releasing hormone (TRH)-induced behaviour in rabbits. Eur J Pharmacol (1991) 0.76
The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron (2003) 6.05
Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron (2009) 5.50
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (2002) 4.72
Lighting up the senses: FM1-43 loading of sensory cells through nonselective ion channels. J Neurosci (2003) 4.28
Cell type–specific channelrhodopsin-2 transgenic mice for optogenetic dissection of neural circuitry function. Nat Methods (2011) 4.02
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature (2005) 3.63
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
The pathophysiological basis of dystonias. Nat Rev Neurosci (2008) 3.46
Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab (2007) 3.43
Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task. Proc Natl Acad Sci U S A (2008) 3.35
CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med (2004) 3.03
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Dynamic analysis of learning in behavioral experiments. J Neurosci (2004) 2.58
Role of signal transducer and activator of transcription 3 in regulation of hypothalamic proopiomelanocortin gene expression by leptin. Endocrinology (2003) 2.56
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Prolonged dopamine signalling in striatum signals proximity and value of distant rewards. Nature (2013) 2.36
Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science (2013) 2.21
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest (2007) 2.05
Synchronous, focally modulated beta-band oscillations characterize local field potential activity in the striatum of awake behaving monkeys. J Neurosci (2003) 2.05
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A (2005) 1.88
Learning-related coordination of striatal and hippocampal theta rhythms during acquisition of a procedural maze task. Proc Natl Acad Sci U S A (2007) 1.86
Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat (2011) 1.85
Differential dynamics of activity changes in dorsolateral and dorsomedial striatal loops during learning. Neuron (2010) 1.84
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
Deletion of the Nhlh2 transcription factor decreases the levels of the anorexigenic peptides alpha melanocyte-stimulating hormone and thyrotropin-releasing hormone and implicates prohormone convertases I and II in obesity. Endocrinology (2003) 1.73
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. Endocrinology (2006) 1.71
A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets. J Exp Med (2007) 1.67
Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther (2004) 1.65
SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab (2010) 1.64
Neural representation of time in cortico-basal ganglia circuits. Proc Natl Acad Sci U S A (2009) 1.64
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci (2006) 1.59
Localized microstimulation of primate pregenual cingulate cortex induces negative decision-making. Nat Neurosci (2012) 1.57
Characterization of the functional MRI response temporal linearity via optical control of neocortical pyramidal neurons. J Neurosci (2011) 1.56
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem (2007) 1.55
Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis (2007) 1.53
Corticostriatal Interactions during Learning, Memory Processing, and Decision Making. J Neurosci (2009) 1.51
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol (2004) 1.46
Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol (2008) 1.45
Antiepileptic treatment for anti-NMDA receptor encephalitis: the need for video-EEG monitoring. Epileptic Disord (2013) 1.42
Afferents to the cerebellar cortex in the cat: evidence for an intrinsic pathway leading from the deep nuclei to the cortex. 1976. Cerebellum (2010) 1.41
Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci (2005) 1.41
Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem (2007) 1.41
Striatal volume predicts level of video game skill acquisition. Cereb Cortex (2010) 1.40
TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis (2003) 1.39
Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging (2004) 1.37
Representation of action sequence boundaries by macaque prefrontal cortical neurons. Science (2003) 1.37
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain (2009) 1.35
Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One (2009) 1.34
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet (2002) 1.33
A dual operator view of habitual behavior reflecting cortical and striatal dynamics. Neuron (2013) 1.31
A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A (2007) 1.30
Oscillations of local field potentials in the rat dorsal striatum during spontaneous and instructed behaviors. J Neurophysiol (2007) 1.25
Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking. Curr Protoc Neurosci (2008) 1.24
Reversible online control of habitual behavior by optogenetic perturbation of medial prefrontal cortex. Proc Natl Acad Sci U S A (2012) 1.24
Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci (2005) 1.24
Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J Neurosci (2004) 1.23
Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis (2007) 1.22
A network representation of response probability in the striatum. Neuron (2002) 1.22
Concurrent activation of dopamine D1 and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization. J Neurosci (2002) 1.21
MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci (2013) 1.21
Habit learning is associated with major shifts in frequencies of oscillatory activity and synchronized spike firing in striatum. Proc Natl Acad Sci U S A (2011) 1.21
Stable encoding of task structure coexists with flexible coding of task events in sensorimotor striatum. J Neurophysiol (2009) 1.20
The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIbbeta3. Blood (2005) 1.15
LRRK2 secretion in exosomes is regulated by 14-3-3. Hum Mol Genet (2013) 1.15
Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord (2005) 1.13
Regulation of hypothalamic prohormone convertases 1 and 2 and effects on processing of prothyrotropin-releasing hormone. J Clin Invest (2004) 1.13
L-type Ca2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment. J Neurosci (2004) 1.12
Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet (2004) 1.12
Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiol Dis (2009) 1.12
Altered dendritic morphology of Purkinje cells in Dyt1 ΔGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice. PLoS One (2011) 1.10
Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet (2002) 1.09
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging (2002) 1.09
Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov Disord (2007) 1.09
Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci U S A (2008) 1.09
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Age-related changes in the protein expression of subunits of the NMDA receptor. Brain Res Mol Brain Res (2002) 1.08
Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. Proc Natl Acad Sci U S A (2009) 1.07
Pathophysiology of Tourette's syndrome: striatal pathways revisited. Brain Dev (2003) 1.06